Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMimi LoTFTimothy T. FerngCSCatherine C. Smith

Discussion

Loading...

Member takes

Overview

Modification of hyperCVAD with Blinatumomab improves remission rates in adults with B-ALL, suggesting enhanced disease control.

Key Points

  • Investigate the efficacy of a modified hyperCVAD regimen combined with Blinatumomab for treating Philadelphia negative B-ALL.
  • A modified hyperCVAD/Blin regimen was used in adult patients with high-risk B-ALL.
  • Patients received cycles of hyperCVAD followed by courses of Blinatumomab and maintenance therapy.
  • Inclusion of rituximab was based on CD20 expression in initial treatments.
  • Bone marrow evaluations utilized traditional cytogenetics, ALL FISH, and NGS for assessment.
  • Complete remission rate after initial therapy reached 82%, with subsequent rates of 95%.
  • Median relapse-free survival (RFS) at 1 year was 66%, and overall survival (OS) was 94%.
  • Patients unable to proceed to alloHCT had a median RFS of 4 months, but OS was 16.6 months.

Cite This Study

Lo et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4e3https://doi.org/10.1182/blood-2025-6861
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk factors for relapse and post-relapse outcomes in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia receiving frontline blinatumomab-based regimens2025 · 1 citations
  2. 2Blinatumomab before and after allogeneic hematopoietic stem cell transplantation in adult patients with B-cell acute lymphoblastic leukemia2025
  3. 3Comparing the impact of blinatumomab therapy versus standard chemotherapy on the progression of relapsed/refractory pediatric B-ALL: a two-center retrospective cohort study2026
  4. 4Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol2024
  5. 5Predictors of Relapse and Post‐Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome‐Negative B‐ <scp>ALL</scp>2026